C16orf65 Inhibitors
Chemical inhibitors of C16orf65 function through diverse mechanisms to impede its activity by targeting various kinases and signaling pathways that are necessary for its regulation. Alsterpaullone, by inhibiting cyclin-dependent kinases (CDKs), can indirectly inhibit C16orf65 by preventing the phosphorylation of proteins that C16orf65 may rely on for its activity. Similarly, Indirubin-3'-monoxime and Roscovitine target CDKs, which are crucial for cell cycle progression. The inhibition of these kinases can lead to a reduction in C16orf65 activity if it is dependent on the cell cycle or phosphorylation events controlled by CDKs. SP600125, which inhibits c-Jun N-terminal kinase (JNK), can modulate C16orf65 activity by affecting the JNK signaling pathway. PD98059 and SB203580, inhibitors of MEK and p38 MAPK, respectively, can lead to the inhibition of C16orf65 by suppressing the activation of ERK and p38 MAPK pathways, which may be involved in the regulation of C16orf65.
Further influencing the signaling cascades that govern C16orf65, LY294002 and Wortmannin, both PI3K inhibitors, can prevent the activation of the PI3K/Akt pathway, which is integral to many cellular processes. This inhibition can result in decreased activity of C16orf65 if it is a part of this pathway. Rapamycin, an inhibitor of mTOR, acts downstream in the PI3K/AKT/mTOR pathway, and its inhibitory effect can extend to C16orf65 if it operates within this signaling cascade. Additionally, multi-targeted kinase inhibitors such as Sunitinib and Sorafenib, which target receptor tyrosine kinases, can indirectly reduce the activity of C16orf65 by preventing the phosphorylation and activation of the protein through these kinases. These chemical inhibitors collectively demonstrate a range of strategies by which they can impede the functional activity of C16orf65, through the obstruction of kinase activity and signaling pathways that are otherwise necessary for its regulation.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone is known to inhibit cyclin-dependent kinases (CDKs). C16orf65, involved in cell cycle regulation, could be functionally inhibited by the suppression of CDKs which are essential for cell cycle progression and therefore indirectly inhibit the activity of C16orf65. | ||||||
5-Iodotubercidin | 24386-93-4 | sc-3531 sc-3531A | 1 mg 5 mg | $150.00 $455.00 | 20 | |
5-Iodotubercidin is an adenosine kinase inhibitor. By inhibiting adenosine kinase, it increases the levels of adenosine which can inhibit various kinases. C16orf65 activity could be inhibited due to the kinase inhibition, which can indirectly affect proteins regulated by phosphorylation. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $77.00 $315.00 $658.00 | 1 | |
This molecule is an inhibitor of CDKs and GSK-3β. By inhibiting these kinases, it may inhibit the phosphorylation of C16orf65, assuming that C16orf65 requires such phosphorylation for its activity. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $92.00 $260.00 | 42 | |
As a CDK inhibitor, Roscovitine can indirectly inhibit C16orf65 by preventing the phosphorylation of proteins that are necessary for its function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). By inhibiting JNK, SP600125 could reduce the functional activity of C16orf65 if JNK is necessary for the activation or stabilization of C16orf65. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that can inhibit the ERK pathway. Should C16orf65 be an effector in this pathway, its activity would be hindered by the lack of ERK activation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
This compound is a p38 MAPK inhibitor, which could inhibit C16orf65 by hindering the p38 MAPK pathway, known to be involved in stress responses and potentially in regulating C16orf65 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that can impede the PI3K/Akt pathway, a signal transduction pathway known to regulate various cellular processes. Inhibition of this pathway can indirectly lead to the functional inhibition of C16orf65. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, which could lead to the inhibition of C16orf65 by disrupting PI3K-dependent pathways necessary for C16orf65 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which is part of the PI3K/AKT/mTOR pathway. Inhibition of this pathway can indirectly inhibit C16orf65 if it is involved in signaling cascades that are downstream of mTOR. | ||||||